Investor Relations

Company Overview

Skye Bioscience Inc. is a biopharmaceutical company focused on the development of proprietary, synthetic cannabinoid derived molecules for the treatment of diseases with significant unmet needs. The company’s lead molecule, in preclinical studies, has demonstrated potential as a new class of therapy to lower intraocular pressure in patients with glaucoma or elevated intraocular pressure that is superior to currently available drugs.

View Management Team View Board of Directors

Investor Resources

Fact Sheet

Corporate Presentation

View Fact Sheet View Corporate Presentation

Latest News

View all news

Jun 10, 2021

Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades

May 17, 2021

Skye Bioscience’s THCVHS Demonstrates Superior Therapeutic Benefit Compared to Glaucoma Standard of Care, both as Combination and Single Agent, in Preclinical Study

Apr 22, 2021

Skye Bioscience Completes CMC and GLP Production for THCVHS Lead Program

View all news

Latest Financial Results

FY 2020

Fiscal Year Ended Dec 31, 2020

10-K

PDF HTML

XBRL

ZIP XLS HTML

For complete information regarding our financials, see our periodic filings

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2020

View 10-K

Email Alerts

Stay informed and receive updates directly to your inbox.

IR Contacts

Company

Skye Bioscience, Inc.
5910 Pacific Center Blvd.
Suite 320
San Diego, CA 92121

Investor Relations

SKYE Investor Relations
T: (858) 410-0266
ir@skyebioscience.com

Transfer Agent

ClearTrust, LLC
16540 Pointe Village Dr.
Suite 210
Lutz, FL 33558
T: 813-235-4490
www.ClearTrustOnline.com

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.